The trademark application tknife was filed by T-knife GmbH, a corporation established under the laws of the Federal Republic of Germany (the "Applicant"). The application was published for oppositions on August 5, 2020, and it was registered by office on November 13, 2020 without any oppositions.
The application was filed in German (English was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
T-cells
T-cell therapy
Pharmaceutical and veterinary preparations for the treatment of cancer and severe immune system disorders
Medicine and therapeutic medicine to prevent and treat cancer.
The mark was filed in class 31 with Transgenic animals and plants for research and for the production of pharmaceutical, veterinary and biochemical goods.
The mark was filed in class 42 with following description of goods:
Research and development in the field of molecular biology, biotechnology, pharmaceutics, immunology and oncology, in particular research and development in the field of medical and veterinary diagnostics and therapy using molecular biological, genetic engineering and biotechnological methods, screening for pharmaceutically active compounds
Development of t-cell therapies for clinical applications
Development of test methods and test kits
Development of adoptive T cell therapy
Development of cellular tumour therapy
Development of tumour markers
Development of diagnostic and therapeutic antibodies
Cell analyses
Individualised medicine, development of treatment plans and therapy adapted for individual patients
DNA screening for scientific research purposes.
The mark was filed in class 44 with following description of goods:
Medical services, In particular extracting of blood and/or tissue samples and analysis and evaluation relating thereto
DNA screening for medical purposes
Medical and health services relating to DNA, genetics and genetic testing
Conducting and evaluating of medical and pharmaceutical studies in the field of t-cell therapy
Medical and pharmaceutical consultancy in the field of t-cell therapy.